<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Prevention of cytomegalovirus disease in kidney transplant recipients
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Prevention of cytomegalovirus disease in kidney transplant recipients
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Prevention of cytomegalovirus disease in kidney transplant recipients
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carlos AQ Santos, MD, MPHS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Vella, MD, FACP, FRCP, FASN, FAST
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel C Brennan, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christophe Legendre, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Emily A Blumberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheila Bond, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1955215416">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cytomegalovirus (CMV) is a globally widespread virus that becomes latent following primary infection but reactivates frequently and causes disease in kidney transplant recipients in the setting of immunocompromise [
         <a href="#rid1">
          1
         </a>
         ]. After kidney transplantation, active CMV infection and disease are associated with increased risk of allograft failure and death; thus, CMV prevention strategies are commonly used in such patients. Preventive therapy decreases reactivation in the setting of latent infection in the transplant recipient and/or acquisition of acute infection in CMV-seronegative recipients of seropositive grafts. However, CMV disease may still occur despite preventive therapies, especially when they are not dosed adequately [
         <a href="#rid2">
          2,3
         </a>
         ]. It also occurs following discontinuation of preventive therapy.
        </p>
        <p>
         This topic reviews the risk factors, clinical significance, and prevention of CMV infection among kidney transplant recipients. The management of active CMV infection and disease in transplant recipients is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7300.html" rel="external">
          "Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients"
         </a>
         .)
        </p>
        <p>
         The diagnosis of CMV infection and the epidemiology, clinical manifestations, and treatment of CMV infection in immunocompetent adults are also discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8291.html" rel="external">
          "Overview of diagnostic tests for cytomegalovirus infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8305.html" rel="external">
          "Approach to the diagnosis of cytomegalovirus infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">
          "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3405320830">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Like other members of the herpesvirus family, CMV establishes
         <strong>
          latent infection
         </strong>
         after the resolution of acute (or primary) infection. Patients who are CMV seropositive have latent infection. Secondary, symptomatic disease may present later, reflecting either reactivation of latent CMV or, less commonly, reinfection with a novel exogenous strain. The risk of CMV reactivation is highest in the setting of systemic immunosuppression.
        </p>
        <p>
         CMV can present in kidney transplant recipients as either CMV infection or CMV disease [
         <a href="#rid1">
          1,4-6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Active CMV infection
         </strong>
         – Defined as the presence of CMV replication in the blood regardless of whether signs or symptoms are present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CMV disease
         </strong>
         – Defined as the presence of detectable CMV in a clinical specimen accompanied by other clinical manifestations. CMV disease may manifest as either CMV syndrome or tissue-invasive CMV disease:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CMV syndrome
         </strong>
         – Defined as the presence of detectable viral replication in blood accompanied by attributable symptoms and signs (eg, fever, malaise, arthralgia, leukopenia, thrombocytopenia) in the absence of tissue-invasive disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tissue-invasive CMV disease
         </strong>
         –
         <strong>
         </strong>
         Patients with
         <strong>
         </strong>
         tissue-invasive CMV disease have clinical symptoms and signs of end-organ disease (eg, enteritis, colitis, hepatitis, nephritis, pneumonitis, meningitis, encephalitis, retinitis). The diagnosis of tissue-invasive disease is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7300.html" rel="external">
          "Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8305.html" rel="external">
          "Approach to the diagnosis of cytomegalovirus infection", section on 'Tissue-invasive disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2502694012">
         <span class="h1">
          IMPORTANCE OF PREVENTION
         </span>
        </p>
        <p class="headingAnchor" id="H297278654">
         <span class="h2">
          Risk factors for infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kidney transplant recipients receive immunosuppressive medications to prevent allograft rejection, which increases their risk of developing CMV infection and disease [
         <a href="#rid1">
          1
         </a>
         ]. The primary risk factor for CMV infection or disease is the CMV serostatus of the donor/recipient pair:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CMV donor-positive/recipient-negative (D+/R-) patients are at the highest risk of developing CMV disease through primary infection with the virus [
         <a href="#rid7">
          7,8
         </a>
         ]. Without preventive therapy, active CMV infection and CMV disease occur in 69 and 56 percent of such patients, respectively [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CMV R+ (D+/R+ or D-/R+) patients have a similar risk of CMV infection as CMV D+/R- patients but are at lower risk of CMV disease. Without preventive therapy, active CMV infection and CMV disease occur in 67 and 20 percent of patients, respectively [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CMV D-/R- patients are at low risk for CMV infection and disease [
         <a href="#rid10">
          10,11
         </a>
         ]. Without preventive therapy, active CMV infection or disease occurs in fewer than 5 percent of patients [
         <a href="#rid10">
          10,11
         </a>
         ]. Such patients may acquire CMV infection from transfusions or community exposures or may have had false negative serology in either the donor or the recipient.
        </p>
        <p>
        </p>
        <p>
         Other risk factors for CMV disease relate to increased net states of immunosuppression and include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of lymphocyte-depleting agents (eg, antithymocyte globulin [ATG]) for induction immunosuppression may increase the risk, particularly in D+/R- patients [
         <a href="#rid12">
          12-16
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         for maintenance immunosuppression [
         <a href="#rid17">
          17
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administration of lymphocyte-depleting therapy or high-dose glucocorticoids to treat acute T cell-mediated rejection or other disorders (eg, gout flares or flares of autoimmune diseases) [
         <a href="#rid18">
          18-20
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphopenia pretransplant or posttransplant [
         <a href="#rid21">
          21,22
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial use of
         <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">
          belatacept
         </a>
         for maintenance immunosuppression [
         <a href="#rid23">
          23
         </a>
         ] or conversion to belatacept for rescue of kidney function [
         <a href="#rid24">
          24
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypogammaglobulinemia [
         <a href="#rid25">
          25,26
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Multiple organ transplantation, such as combined kidney-pancreas transplantation, also appears to increase the risk of developing CMV infection or disease [
         <a href="#rid27">
          27
         </a>
         ]. This may be related to the higher-intensity immunosuppressive regimens used with multiple organ transplantation and/or the greater likelihood of transmitting virus from donor to recipient with larger volumes of tissue.
        </p>
        <p>
         Immune monitoring assays that measure CMV-specific T cell responses, such as the QuantiFERON-CMV [
         <a href="#rid28">
          28
         </a>
         ] and ELISPOT [
         <a href="#rid29">
          29
         </a>
         ], may be useful adjuncts in identifying patients at increased risk of CMV disease [
         <a href="#rid28">
          28,30,31
         </a>
         ]. However, studies demonstrating safety and cost effectiveness of changing management based on results of immune assays are needed before these assays can be used widely [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1563671468">
         <span class="h2">
          Impact on graft function and mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         CMV increases mortality and graft loss. Natural history studies have demonstrated that active CMV infection and disease are associated with a 1.4- and 2.5-fold increased risk of acute allograft rejection, respectively, and a 2.8- and 4.7-fold increased risk of death, respectively [
         <a href="#rid9">
          9,33-35
         </a>
         ].
        </p>
        <p>
         CMV has both direct and indirect effects on kidney transplant outcomes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Direct effects of CMV infection are cytopathic effects on kidney allograft cells that can lead to nephropathy and allograft loss [
         <a href="#rid35">
          35-38
         </a>
         ], as well as morbidity and death from severe CMV disease [
         <a href="#rid2">
          2,3,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Indirect effects of CMV infection are upregulation of human leukocyte antigens and adhesion molecules that can promote acute allograft rejection; allograft loss; death; bacterial, fungal, and viral infections; cardiovascular disease; and posttransplant lymphoproliferative disorder [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H495083097">
         <span class="h1">
          PREVENTION OF DISEASE
         </span>
        </p>
        <p class="headingAnchor" id="H1340041524">
         <span class="h2">
          Preventive strategies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because CMV causes considerable morbidity and mortality and has been identified as a risk factor for rejection in kidney transplant recipients, there has been intense interest in prevention. Two strategies are generally used:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Universal prophylaxis
         </strong>
         –
         <strong>
         </strong>
         Universal prophylaxis is the administration of antiviral medication to all transplant recipients or a subset of high-risk patients beginning within 10 days after transplant and continuing for a finite period (eg, three to six months).
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          Valganciclovir
         </a>
         is typically used. (See
         <a class="local">
          'Universal prophylaxis (high risk)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preemptive therapy
         </strong>
         – Preemptive therapy
         <strong>
         </strong>
         refers to monitoring patients for CMV in the blood using quantitative polymerase chain reaction (PCR; viral load) at regular intervals (usually weekly). Oral
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         is initiated when viral replication is detected at a certain threshold. The specific threshold varies by transplant center and by assay. (See
         <a class="local">
          'Preemptive therapy (low risk)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         An additional strategy that combines these two approaches is "surveillance after prophylaxis" (previously termed "hybrid approach"). This strategy is less commonly used. (See
         <a class="local">
          'Surveillance after prophylaxis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4164642686">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to CMV prevention, which is consistent with the 2018 international consensus guidelines on the management of CMV in solid organ transplantation [
         <a href="#rid1">
          1
         </a>
         ], is presented below.
        </p>
        <p class="headingAnchor" id="H739838478">
         <span class="h3">
          Universal prophylaxis (high risk)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all kidney transplant recipients who are CMV seropositive or who have received an organ from a CMV-seropositive donor (CMV D+/R+, D-/R+, D+/R-), we suggest universal prophylaxis rather than preemptive therapy. We prefer universal prophylaxis over preemptive therapy, given its ease of administration and prevention of potentially harmful low-level CMV replication.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiviral selection
         </strong>
         – For prophylaxis, we suggest
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         rather than other antiviral agents because of its efficacy and high oral bioavailability.
         <a class="drug drug_general" data-topicid="115632" href="/z/d/drug information/115632.html" rel="external">
          Letermovir
         </a>
         is a reasonable alternative for patients who cannot tolerate valganciclovir due to cytopenias or for patients with delayed graft function or unstable graft function, which can complicate valganciclovir dosing. If letermovir is used, a second drug is required to prevent herpes simplex virus (HSV) infection (eg,
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing –
         </strong>
         We start prophylaxis in the immediate posttransplant period. The duration of prophylaxis depends upon the CMV serotype combination:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For CMV D+/R- patients, we use
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         at 900 mg orally once daily for 200 days following transplantation, with the dose adjusted for kidney function. In patients who cannot tolerate valganciclovir due to cytopenias, or who have delayed or unstable graft function that complicates valganciclovir dosing, we use
         <a class="drug drug_general" data-topicid="115632" href="/z/d/drug information/115632.html" rel="external">
          letermovir
         </a>
         480 mg orally once daily for 200 days following transplantation. Patients receiving letermovir should also receive
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         for HSV and varicella zoster virus (VZV) prophylaxis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For CMV R+ patients, we use
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         at 900 mg orally once daily for 100 days following transplantation, with the dose adjusted for kidney function.
        </p>
        <p>
        </p>
        <p>
         As noted above, CMV D-/R- patients do not generally receive universal prophylaxis for CMV. We give such patients
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         for three months following transplantation for HSV prophylaxis.
        </p>
        <p>
         Support for the use of universal prophylaxis is based upon several randomized trials comparing prophylactic and preemptive strategies among kidney transplant recipients [
         <a href="#rid11">
          11,13,41-48
         </a>
         ]. In a meta-analysis of seven randomized trials (560 patients), rates of CMV infection were higher with preemptive treatment than with universal prophylaxis (relative risk 1.67, 95% CI 1.21-2.30), but there were no significant differences in the rates of CMV disease, acute allograft rejection, graft loss, or death between the two strategies [
         <a href="#rid49">
          49
         </a>
         ]. Similar findings were reported in a randomized trial in 296 kidney transplant recipients (all CMV R+) published after this meta-analysis, which found that universal prophylaxis with oral
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         , compared with preemptive treatment, lowered rates of CMV infection and disease at 12 months posttransplant, particularly in D+/R+ patients (16 versus 54 percent and 4 versus 19 percent, respectively) [
         <a href="#rid46">
          46
         </a>
         ]. A follow-up study found that this benefit persisted up to seven years posttransplant, at which time rates of graft loss, death, and rejection were similar between the groups [
         <a href="#rid47">
          47
         </a>
         ]. A potential downside to universal prophylaxis is a higher risk of late-onset CMV disease (ie, CMV disease occurring after discontinuation of prophylaxis) when compared with a preemptive approach [
         <a href="#rid50">
          50,51
         </a>
         ]. However, the absolute risk of late-onset CMV disease appears to be small, and the likelihood of immune control is greater outside of the early posttransplant period.
        </p>
        <p>
         Another systematic review that included randomized trials as well as observational studies found that preemptive treatment, when initiated at a lower threshold (any level of CMV viremia), was associated with a lower incidence of CMV disease at 12 months posttransplant compared with universal prophylaxis [
         <a href="#rid13">
          13
         </a>
         ]. Similar to the meta-analysis cited above, there was no significant difference in the rates of graft loss, acute allograft rejection, or death at 12 months between these strategies.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          Valganciclovir
         </a>
         is preferred for the prevention of CMV infection after kidney transplantation based upon randomized trials showing its efficacy among kidney transplant recipients [
         <a href="#rid11">
          11,50,52-54
         </a>
         ]. A network meta-analysis comparing valganciclovir, oral or intravenous (IV)
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         , and
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         for the prevention of CMV infection or disease in kidney transplant recipients concluded that among the antiviral therapies, valganciclovir may have the most favorable benefits and risks in this setting [
         <a href="#rid52">
          52
         </a>
         ]. One randomized trial within the meta-analysis that compared valganciclovir (900 mg orally daily) with valacyclovir (2 g four times daily) for three months after transplantation showed similar efficacy in preventing CMV infection and disease between the regimens; however, rates of biopsy-proven acute rejection were higher with valacyclovir (31 versus 17 percent) [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="115632" href="/z/d/drug information/115632.html" rel="external">
          Letermovir
         </a>
         is an alternative to
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         and has also been shown to be effective in preventing CMV disease for D+/R- patients. In a phase 3 trial, 601 D+/R- kidney transplant recipients were randomly assigned to prophylaxis with either letermovir (480 mg orally daily) or valganciclovir (900 mg orally daily) to prevent CMV disease; patients receiving letermovir also received
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         (400 mg twice daily) as HSV and VZV prophylaxis [
         <a href="#rid55">
          55
         </a>
         ]. Rates of CMV disease through 52 weeks posttransplant were comparable between the groups (10.4 versus 11.8 percent). The rate of leukopenia or neutropenia through week 28 posttransplant was lower in the letermovir group compared with the valganciclovir group (26 versus 64 percent), and fewer patients in the letermovir group discontinued prophylaxis due to drug-related adverse events (2.7 versus 8.8 percent).
        </p>
        <p>
         The optimal duration of prophylaxis is unclear. Longer durations of prophylaxis may be preferred since shorter courses have been associated with an increased risk of late-onset CMV disease [
         <a href="#rid50">
          50
         </a>
         ]. One trial showed that
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         given for 200 days decreased the rate of active CMV infection and disease in CMV D+/R- patients compared with valganciclovir given for 100 days [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         The toxicity profile of
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         is similar to that of its parent compound,
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         . Hematologic suppression, in particular leukopenia (including neutropenia), appears to be the most significant and common adverse event associated with these agents. When leukopenia occurs, dose reduction of valganciclovir should be
         <strong>
          avoided
         </strong>
         , given the risk of promoting resistance. Patients should be evaluated for other potential causes of leukopenia (eg,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         ). The addition of granulocyte colony-stimulating factor should be considered before discontinuing valganciclovir. (See
         <a class="medical medical_review" href="/z/d/html/8342.html" rel="external">
          "Ganciclovir and valganciclovir: An overview", section on 'Bone marrow suppression'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3703101934">
         <span class="h3">
          Preemptive therapy (low risk)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients at low risk for CMV infection (ie, CMV D-/R-), we use a preemptive approach. Universal prophylaxis is generally not administered to CMV D-/R- patients beyond administering
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         to prevent HSV infections, given their very low risk of CMV infection and disease.
        </p>
        <p>
         We monitor patients for CMV replication using nucleic acid testing (ie, PCR) weekly for three months following transplantation. If active CMV infection is detected, we give
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         or IV
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         at treatment doses until repeat CMV nucleic acid testing is negative and for a minimum of 21 days. Treatment dosing of valganciclovir is 900 mg orally twice daily and of ganciclovir is 5 mg/kg IV twice daily; doses should be adjusted for kidney function. Viral load thresholds to start preemptive therapy have not been standardized across institutions given variability among diagnostic specimens and testing platforms.
        </p>
        <p>
         If a CMV preemptive strategy is used, we would give HSV prophylaxis with
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         for three months following transplantation. (See
         <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">
          "Prophylaxis of infections in solid organ transplantation", section on 'Herpes simplex and varicella-zoster'
         </a>
         .)
        </p>
        <p>
         As discussed above, we prefer a prophylactic approach over a preemptive approach for kidney transplant recipients at significant risk of active CMV infection and disease. (See
         <a class="local">
          'Universal prophylaxis (high risk)'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3892819835">
         <span class="h3">
          Surveillance after prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some transplant centers employ a hybrid approach, in which the highest-risk patients are given prophylactic anti-CMV medications after transplant but, after completing prophylactic therapy, are monitored regularly for active CMV infection (by PCR of the blood). Among such patients, treatment doses of anti-CMV medications are given if viral replication is detected [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7300.html" rel="external">
          "Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients", section on 'Antiviral therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1546259275">
         <span class="h2">
          Optimization of immunosuppression
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all kidney transplant recipients, maintaining an appropriate balance between over- and underimmunosuppression is critical to care. Overimmunosuppression, particularly lymphopenia, raises the risk of CMV infection [
         <a href="#rid21">
          21,22
         </a>
         ]. Thus, as part of our approach to preventing CMV infection, we pay particular attention to lymphocyte counts and often adjust the immunosuppressive regimen (eg, reduce the antimetabolite dose) when lymphopenia is present, in addition to evaluating for other causes. In a single-center retrospective study of 159 kidney transplant recipients, discontinuation of the antimetabolite upon detection of CMV or BK polyomavirus viremia was associated with a low incidence of biopsy-proven rejection (8.8 percent at a mean of 1.6 years after discontinuation) [
         <a href="#rid57">
          57
         </a>
         ]. This was comparable to the center's overall rejection rate of 4 to 7 percent and the national biopsy-proven rejection rate of 6.8 percent at one year posttransplant as reported by the Scientific Registry of Transplant Recipients. (See
         <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">
          "Overview of care of the adult kidney transplant recipient", section on 'Management of immunosuppression'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2228715492">
         <span class="h2">
          Special considerations
         </span>
        </p>
        <p class="headingAnchor" id="H1552577101">
         <span class="h3">
          Patients treated for rejection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For kidney transplant recipients who are receiving treatment for acute rejection with
         <a class="drug drug_general" data-topicid="10026" href="/z/d/drug information/10026.html" rel="external">
          rabbit antithymocyte globulin
         </a>
         (rATG)-Thymoglobulin,
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         , high-dose glucocorticoids, or plasmapheresis, we recommence CMV prophylaxis. We administer prophylaxis for at least three months with a regimen that is identical to that administered in the immediate posttransplant period. Some centers may not recommence CMV prophylaxis for short courses of high-dose glucocorticoids or plasmapheresis. (See
         <a class="local">
          'Universal prophylaxis (high risk)'
         </a>
         above.)
        </p>
        <p>
         Kidney transplant recipients with acute rejection may be at higher risk for CMV disease. In a retrospective study of 992 kidney transplant recipients, there was no significant difference in the incidence of CMV infection between those who developed acute rejection within six months of transplant and those without rejection (13 versus 10 percent, respectively) [
         <a href="#rid58">
          58
         </a>
         ]. However, the incidence of tissue-invasive CMV disease, particularly gastrointestinal CMV disease, was greater among patients who experienced acute rejection (8 versus 3 percent). Another retrospective study found that transplant failure or rejection was a risk factor for delayed-onset CMV disease in kidney transplant recipients (hazard ratio 3.2) [
         <a href="#rid3">
          3
         </a>
         ]
        </p>
        <p class="headingAnchor" id="H415374069">
         <span class="h3">
          Patients who are critically ill
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not routinely administer CMV prophylaxis to kidney transplant recipients who are critically ill, given insufficient data to support this practice. Although nontransplant patients who are critically ill have an increased risk of CMV infection and reactivation, there is no evidence showing that prophylaxis or suppression of CMV infection improves outcomes in this patient population. (See
         <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">
          "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Reactivation in critically ill patients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1886824714">
         <span class="h3">
          Secondary prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not routinely administer CMV prophylaxis to prevent recurrent CMV infection in kidney transplant recipients who have been treated for CMV infection or disease, especially if the antimetabolite has been discontinued indefinitely. This issue is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7300.html" rel="external">
          "Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients", section on 'Duration of therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1052201742">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109354.html" rel="external">
          "Society guideline links: Cytomegalovirus in solid organ transplant recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H970173284">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors for infection
         </strong>
         – The primary risk factor for CMV infection or disease is the CMV serostatus of the donor/recipient pair. CMV donor-positive/recipient-negative (D+/R-) patients are at the highest risk, CMV R+ patients are at intermediate risk, and CMV D-/R- patients are at low risk. Other risk factors relate to of the type and degree of immunosuppression in the individual patient. (See
         <a class="local">
          'Risk factors for infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact on transplant outcomes
         </strong>
         – Through direct and indirect effects, active CMV infection and disease are associated with an increased risk of acute allograft rejection, death, other infections, cardiovascular disease, and posttransplant lymphoproliferative disorder. (See
         <a class="local">
          'Impact on graft function and mortality'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preventive strategies
         </strong>
         – There are two main strategies for CMV prevention: universal prophylaxis (administration of an antiviral for a finite period posttransplantation) and preemptive therapy (monitoring for active CMV replication in the blood at regular intervals by quantitative polymerase chain reaction [PCR] and initiating antiviral therapy if replication meets a certain threshold). (See
         <a class="local">
          'Preventive strategies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Our approach to prophylaxis
         </strong>
         –
         <strong>
         </strong>
         Our approach to CMV prevention is consistent with the 2018 international consensus guidelines on the management of CMV in solid organ transplantation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Universal prophylaxis for high-risk patients
         </strong>
         – For all kidney transplant recipients who are CMV seropositive or who have received an organ from a CMV-seropositive donor (CMV D+/R+, D-/R+, D+/R-), we suggest universal prophylaxis rather than preemptive therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We prefer universal prophylaxis over preemptive therapy, given its ease of administration and prevention of potentially harmful low-level CMV replication. For prophylaxis, we suggest
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         rather than other antiviral agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Valganciclovir is effective at reducing the risk of CMV infection and disease. Duration of prophylactic valganciclovir depends upon the CMV serotype combination and on the patient's estimated glomerular filtration rate (eGFR).
         <a class="drug drug_general" data-topicid="115632" href="/z/d/drug information/115632.html" rel="external">
          Letermovir
         </a>
         is a reasonable alternative for patients who cannot tolerate valganciclovir due to cytopenias or for patients with delayed graft function or unstable graft function. If letermovir is used, a second drug is required to prevent herpes simplex virus (HSV) infection (eg,
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         ). (See
         <a class="local">
          'Universal prophylaxis (high risk)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preemptive therapy for low-risk patients
         </strong>
         – For low-risk patients (CMV D-/R-), we use a preemptive approach and monitor patients for CMV replication using nucleic acid testing (ie, PCR) weekly for three months following transplantation. We give these patients
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         to prevent active HSV infection. (See
         <a class="local">
          'Preemptive therapy (low risk)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Optimizing immunosuppression
         </strong>
         – For all kidney transplant recipients, maintaining an appropriate balance between over- and underimmunosuppression is critical to care. Thus, as part of our approach to preventing CMV infection, we pay particular attention to lymphocyte counts and commonly adjust the immunosuppressive regimen (eg, reduce the antimetabolite dose) when lymphopenia is present, in addition to evaluating for other causes. (See
         <a class="local">
          'Optimization of immunosuppression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1876884357">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges William M Bennett, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos CA, Brennan DC, Fraser VJ, Olsen MA. Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation. Transplantation 2014; 98:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos CA, Brennan DC, Olsen MA. Accuracy of Inpatient International Classification of Diseases, Ninth Revision, Clinical Modification Coding for Cytomegalovirus After Kidney Transplantation. Transplant Proc 2015; 47:1772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation 2018; 102:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos CAQ, Brennan DC. Cytomegalovirus: A Guide for the Perplexed. Transplantation 2018; 102:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbott KC, Hypolite IO, Viola R, et al. Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Ann Epidemiol 2002; 12:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 2006; 82:S15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harvala H, Stewart C, Muller K, et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol 2013; 85:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6:2134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luan FL, Samaniego M, Kommareddi M, et al. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients. Transpl Infect Dis 2010; 12:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar L, Murray-Krezan C, Singh N, et al. A Systematic Review and Meta-analysis of Optimized CMV Preemptive Therapy and Antiviral Prophylaxis for CMV Disease Prevention in CMV High-Risk (D+R-) Kidney Transplant Recipients. Transplant Direct 2023; 9:e1514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355:1967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Paula MI, Bowring MG, Shaffer AA, et al. Decreased incidence of acute rejection without increased incidence of cytomegalovirus (CMV) infection in kidney transplant recipients receiving rabbit anti-thymocyte globulin without CMV prophylaxis - a cohort single-center study. Transpl Int 2021; 34:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tedesco-Silva H, Felipe C, Ferreira A, et al. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. Am J Transplant 2015; 15:2655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarmiento JM, Dockrell DH, Schwab TR, et al. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000; 14:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010; 70:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conti DJ, Freed BM, Singh TP, et al. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Arch Surg 1995; 130:1217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardiner BJ, Nierenberg NE, Chow JK, et al. Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients. Clin Infect Dis 2018; 67:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corona-Nakamura AL, Monteón-Ramos FJ, Troyo-Sanromán R, et al. Incidence and predictive factors for cytomegalovirus infection in renal transplant recipients. Transplant Proc 2009; 41:2412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karadkhele G, Hogan J, Magua W, et al. CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept. Am J Transplant 2021; 21:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chavarot N, Divard G, Scemla A, et al. Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept. Am J Transplant 2021; 21:2448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarmiento E, Jimenez M, di Natale M, et al. Secondary antibody deficiency is associated with development of infection in kidney transplantation: Results of a multicenter study. Transpl Infect Dis 2021; 23:e13494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mawhorter S, Yamani MH. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schachtner T, Zaks M, Otto NM, et al. Simultaneous pancreas/kidney transplant recipients are predisposed to tissue-invasive cytomegalovirus disease and concomitant infectious complications. Transpl Infect Dis 2017; 19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013; 56:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barabas S, Spindler T, Kiener R, et al. An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity. BMC Immunol 2017; 18:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bestard O, Lucia M, Crespo E, et al. Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. Am J Transplant 2013; 13:1793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Ruiz M, Rodríguez-Goncer I, Parra P, et al. Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin. Am J Transplant 2020; 20:2070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar D, Mian M, Singer L, Humar A. An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation. Am J Transplant 2017; 17:2468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hakimi Z, Aballéa S, Ferchichi S, et al. Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting. Transpl Infect Dis 2017; 19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birk PE, Chavers BM. Does cytomegalovirus cause glomerular injury in renal allograft recipients? J Am Soc Nephrol 1997; 8:1801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vichot AA, Formica RN Jr, Moeckel GW. Cytomegalovirus glomerulopathy and cytomegalovirus interstitial nephritis on sequential transplant kidney biopsies. Am J Kidney Dis 2014; 63:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liapis H, Storch GA, Hill DA, et al. CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR. Nephrol Dial Transplant 2003; 18:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borchers AT, Perez R, Kaysen G, et al. Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. Transpl Immunol 1999; 7:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths P. The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination. Antiviral Res 2020; 176:104732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365:2105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strippoli GF, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witzke O, Hauser IA, Bartels M, et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 2012; 93:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witzke O, Nitschke M, Bartels M, et al. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial. Transplantation 2018; 102:876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reischig T, Vlas T, Kacer M, et al. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients. J Am Soc Nephrol 2023; 34:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang LF, Wang YT, Tian JH, et al. Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials. Transpl Infect Dis 2011; 13:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10:1228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaminski H, Couzi L, Garrigue I, et al. Easier Control of Late-Onset Cytomegalovirus Disease Following Universal Prophylaxis Through an Early Antiviral Immune Response in Donor-Positive, Recipient-Negative Kidney Transplants. Am J Transplant 2016; 16:2384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruenroengbun N, Numthavaj P, Sapankaew T, et al. Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta-analysis. Transpl Int 2021; 34:2720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reischig T, Kacer M, Jindra P, et al. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. Clin J Am Soc Nephrol 2015; 10:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Limaye AP, Budde K, Humar A, et al. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA 2023; 330:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Razonable RR, Humar A, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubrawka CA, Progar KJ, January SE, et al. Impact of antimetabolite discontinuation following cytomegalovirus or BK polyoma virus infection in kidney transplant recipients. Transpl Infect Dis 2022; 24:e13931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee YM, Kim YH, Han DJ, et al. Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients. Transpl Infect Dis 2014; 16:397.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 105281 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30817026" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18260785" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24621539" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26293049" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Accuracy of Inpatient International Classification of Diseases, Ninth Revision, Clinical Modification Coding for Cytomegalovirus After Kidney Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29596116" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29677079" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cytomegalovirus: A Guide for the Perplexed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12160599" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hospitalizations for cytomegalovirus disease after renal transplantation in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19422346" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16858268" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The natural course of cytomegalovirus infection and disease in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23508914" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16780548" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20576019" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37456587" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A Systematic Review and Meta-analysis of Optimized CMV Preemptive Therapy and Antiviral Prophylaxis for CMV Disease Prevention in CMV High-Risk (D+R-) Kidney Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17093248" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33314321" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Decreased incidence of acute rejection without increased incidence of cytomegalovirus (CMV) infection in kidney transplant recipients receiving rabbit anti-thymocyte globulin without CMV prophylaxis - a cohort single-center study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25988935" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10770418" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20481654" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : New developments in the management of cytomegalovirus infection after solid organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7762909" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7487465" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29635432" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19715936" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Incidence and predictive factors for cytomegalovirus infection in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32519434" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33283406" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33064917" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Secondary antibody deficiency is associated with development of infection in kidney transplantation: Results of a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19060546" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hypogammaglobulinemia and infection risk in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28665480" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Simultaneous pancreas/kidney transplant recipients are predisposed to tissue-invasive cytomegalovirus disease and concomitant infectious complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23196955" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28270111" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : An optimized IFN-γELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23711167" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31991045" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γrelease assay in kidney transplant recipients treated with antithymocyte globulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28500691" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12392291" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15200441" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28599091" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9355085" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Does cytomegalovirus cause glomerular injury in renal allograft recipients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24568687" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Cytomegalovirus glomerulopathy and cytomegalovirus interstitial nephritis on sequential transplant kidney biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12543898" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10544437" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32081353" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17973956" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15964447" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16436954" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16365468" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18261177" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22094954" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29166336" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36749127" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21599818" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20353469" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26953216" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Easier Control of Late-Onset Cytomegalovirus Disease Following Universal Prophylaxis Through an Early Antiviral Immune Response in Donor-Positive, Recipient-Negative Kidney Transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34580930" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25424991" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15023154" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37279999" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23465003" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Cytomegalovirus in solid organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35980197" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Impact of antimetabolite discontinuation following cytomegalovirus or BK polyoma virus infection in kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24810355" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
